Synvista Therapeutics, Inc.
Share · US87164M1009 (OTC)
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of Synvista Therapeutics, Inc.
No Price
Company Profile for Synvista Therapeutics, Inc. Share
Synvista Therapeutics, Inc., a product-based biopharmaceutical company, develops diagnostic tests and drugs to identify and treat diabetic patients at high risk for the development of cardiovascular disease. The company's products include ALT-2074, a glutathione peroxidase mimetic in Phase II clinical trials for the treatment of diabetic patients with Hp2-2; and Alagebrium chloride or alagebrium, an Advanced Glycation End-product Crosslink Breaker in Phase II clinical trials for the treatment of diastolic heart failure and diabetic nephropathy. It is also developing a diagnostic test to identify and treat patients with diabetes who are in risk of cardiovascular disease. The company, formerly known as Alteon, Inc., was founded in 1986 and is headquartered in Montvale, New Jersey.
Company Data
Name Synvista Therapeutics, Inc.
Company Synvista Therapeutics, Inc.
Primary Exchange 
UTC
UTC
ISIN US87164M1009
Asset Class Share
Sector Healthcare
Industry Medical - Pharmaceuticals
Country United States of America
Currency USD
Employees 0,0 T
Address 221 West Grand Avenue, Parsippany
IPO Date 2000-01-03
Stock Splits
| Date | Split |
|---|---|
| 19.06.2008 | 1:28 |
| 25.07.2007 | 1:50 |
| 31.05.2007 | 1:20 |
ID Changes
| Date | From | To |
|---|---|---|
| 15.01.2009 | SYI | SYNI |
Ticker Symbols
| Name | Symbol |
|---|---|
| Over The Counter | SYNI |
More Shares
Investors who hold Synvista Therapeutics, Inc. also have the following shares in their portfolio:
